Joseph Visconti
Family · Southaven, MSNPI 1699773820
Payments from drug & device makers
Across 154 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$419
- GSK$412
- AstraZeneca$383
- Novo Nordisk$276
- Boehringer Ingelheim$227
- Bayer$207
- plus $686 from 16 others
What the payments were for
- Food & beverage$2,610100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $419 |
| GSK | 30 | $412 |
| AstraZeneca | 24 | $383 |
| Novo Nordisk | 16 | $276 |
| Boehringer Ingelheim | 12 | $227 |
| Bayer | 11 | $207 |
| Amarin Pharma, Inc. | 8 | $183 |
| Lilly USA, LLC | 7 | $114 |
| Shield Therapeutics Inc | 3 | $48 |
| Exact Sciences | 3 | $46 |
| Astellas Pharma US Inc | 2 | $40 |
| Pfizer | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Boston Scientific | 2 | $35 |
| Merck | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Scynexis, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,610 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $29,529 |
| MounjaroTirzepatide | 14 | $15,998 |
| TrulicityDulaglutide | 11 | $12,329 |
| JardianceEmpagliflozin | 12 | $12,128 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $10,367 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,434 |
| FenofibrateFenofibrate Nanocrystallized | 59 | $1,414 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,192 |
| Atorvastatin Calcium | 100 | $1,142 |
| SynthroidLevothyroxine Sodium | 19 | $1,128 |
| Rosuvastatin Calcium | 114 | $962 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 11 | $771 |
| Amlodipine Besylate | 133 | $610 |
| Zolpidem Tartrate | 77 | $604 |
| Gabapentin | 62 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $412 | $29,52938 claims |
| Lilly USA, LLCMounjaro, Trulicity | $114 | $28,32725 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $227 | $22,49529 claims |
| AbbVieSynthroid | $16 | $1,12819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Southaven
- Lindsey GarnerSouthaven$16K
- Angela UgwuanyiSouthaven$13K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.